S-Ruxolitinib INCB018424 INCB-018424 CAS: 941685-37-6

CAS NO: 941685-37-6
S-Ruxolitinib INCB018424 INCB-018424
Chemical Name: S-Ruxolitinib (INCB018424)
Molecular Formula: C17H17N6
Formula Weight: 305.35708
CAS No.: 941685-37-6
Description Review
Description

S-Ruxolitinib, also known as INCB018424 or INCB-018424, is a small molecule inhibitor of Janus kinase (JAK) 1 and JAK 2. This product is a white to off-white powder with the chemical formula C17H18N6O and a molecular weight of 306.37 g/mol. Its CAS number is 941685-37-6.

Top ten keywords from Google and synonyms

  1. S-Ruxolitinib
  2. INCB018424
  3. JAK inhibitor
  4. Myelofibrosis
  5. Polycythemia vera
  6. Immune disorders
  7. Rheumatoid arthritis
  8. Cancer therapy
  9. Inflammatory bowel disease
  10. Alopecia areata

Synonyms:

  • INCB018424 phosphate
  • Ruxolitinib S enantiomer
  • S-INCB-18424

Health benefits of S-Ruxolitinib

S-Ruxolitinib has shown potential health benefits in various areas such as myelofibrosis, polycythemia vera, and immune disorders.

Myelofibrosis and Polycythemia Vera: S-Ruxolitinib has been FDA-approved for the treatment of intermediate or high-risk myelofibrosis and polycythemia vera. These are rare blood cancers characterized by abnormal red blood cell production and bone marrow fibrosis. S-Ruxolitinib inhibits JAK1 and JAK2, which are involved in the signaling pathways that lead to inflammation and cell proliferation. By inhibiting these pathways, S-Ruxolitinib reduces the symptoms associated with these diseases, such as fatigue, spleen enlargement, and night sweats.

Immune Disorders: S-Ruxolitinib has also shown promise in the treatment of immune disorders such as rheumatoid arthritis and inflammatory bowel disease. The inhibition of JAK1 and JAK2 leads to a reduction in inflammation, which is a key contributor to the pathogenesis of these diseases.

Potential Effects

S-Ruxolitinib has shown potential as a therapeutic agent in the treatment of myelofibrosis, polycythemia vera, and immune disorders such as rheumatoid arthritis and inflammatory bowel disease.

Product Mechanism

As an inhibitor of JAK1 and JAK2, S-Ruxolitinib blocks a signaling pathway that leads to inflammation and cell proliferation. By inhibiting this pathway, it reduces the symptoms associated with myelofibrosis, polycythemia vera, and immune disorders.

Safety

While S-Ruxolitinib has shown promising results in clinical trials, further investigation into its safety in humans is required. Animal studies have not shown significant adverse effects, but more research is needed to fully understand its safety profile.

Side Effects

The most common side effects associated with S-Ruxolitinib include anemia, thrombocytopenia (low platelet count), and infection. Less common side effects include dizziness, headache, and gastrointestinal upset.

Dosing Information

S-Ruxolitinib dosing information varies depending on the condition being treated. Patients should consult with their healthcare provider for specific dosing guidelines.

Conclusion

S-Ruxolitinib has shown significant potential as a therapeutic agent in various fields of medicine, particularly in the treatment of myelofibrosis, polycythemia vera, and immune disorders such as rheumatoid arthritis and inflammatory bowel disease. Its mechanism of action in inhibiting JAK1 and JAK2 provides a novel approach to reducing inflammation and cell proliferation, which are key contributors to the pathogenesis of these diseases. While more research is needed to establish safety and dosing guidelines for human use, S-Ruxolitinib shows promise as a potential treatment option

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code
Message Us